Holen Sie sich die Stockscreener-App
50.69
0.62%
0.31
Schlusskurs vom Vortag:
$50.38
Offen:
$50.73
24-Stunden-Volumen:
414.36K
Relative Volume:
0.59
Marktkapitalisierung:
$3.33B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-8.5337
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-2.18%
1M Leistung:
+12.02%
6M Leistung:
+49.40%
1J Leistung:
+95.41%
1-Tages-Spanne:
$50.03
$51.17
1-Wochen-Bereich:
$49.39
$52.95
52-Wochen-Spanne:
$24.00
$54.16
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
50.69 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics CEO Matthew Klein sells $390,457 in stock By Investing.com - Investing.com Nigeria
PTC Therapeutics CFO sells $117,006 in stock By Investing.com - Investing.com South Africa
PTC Therapeutics CFO sells $117,006 in stock - Investing.com India
PTC Therapeutics EVP Scott sells $88,045 in stock - Investing.com India
PTC Therapeutics' chief accounting officer sells $88,043 in stock - Investing.com
PTC Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
PTC Therapeutics (NASDAQ:PTCT) Downgraded by StockNews.com to "Hold" - MarketBeat
PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia - Marketscreener.com
How PTC Therapeutics Will Shape Its Story at Two Major Healthcare Conferences - StockTitan
Vontobel Holding Ltd. Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
FDA accepts new drug application for vatiquinone to treat Friedreich's ataxia - Contemporary Pediatrics
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $63.00 - MarketBeat
PTC Therapeutics Says FDA Grants Priority Review to Vatiquinone NDA for Treating Friedreich's Ataxia; Shares Up Pre-Bell - Marketscreener.com
FDA grants priority review for potential Friedreich's ataxia drug - Investing.com India
Ptc Therapeutics Announces FDA Acceptance And Priority Review For Vatiquinone NDA - TradingView
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential - StockTitan
RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating - Marketscreener.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Apollon Wealth Management LLC - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $45.00 - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results - Quantisnow
PTC Therapeutics' (NASDAQ:PTCT) investors will be pleased with their solid 101% return over the last year - Simply Wall St
PTC Therapeutics (NASDAQ:PTCT) Upgraded at StockNews.com - MarketBeat
(PTCT) Trading Report - Stock Traders Daily
PTC Therapeutics rises 9% after Cantor raises price target to Street high - MSN
Rett Syndrome Market Growth Projections 2024-2034: - openPR
PTC Therapeutics (NASDAQ:PTCT) Trading 6.1% Higher Following Analyst Upgrade - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $113.00 at Cantor Fitzgerald - MarketBeat
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges - MSN
Cantor Fitzgerald Issues Negative Estimate for PTCT Earnings - MarketBeat
Duchenne Muscular Dystrophy Market Report 2034: Epidemiology - openPR
PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald - Yahoo Finance
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? - Yahoo Finance
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113 By Investing.com - Investing.com Canada
Why PTC Therapeutics (PTCT) Stock Is Rallying Today - Insider Monkey
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113 - MSN
Cowen raises PTC Therapeutics stock price target to $50 - MSN
Cowen raises PTC Therapeutics stock price target to $50 By Investing.com - Investing.com Nigeria
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER |
Feb 20 '25 |
Sale |
50.12 |
878 |
44,009 |
62,564 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER |
Feb 19 '25 |
Sale |
50.10 |
1,168 |
58,512 |
75,603 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER |
Feb 20 '25 |
Sale |
50.12 |
1,167 |
58,495 |
74,436 |
| Pauwels Eric | CHIEF EXECUTIVE OFFICER |
Feb 20 '25 |
Sale |
50.12 |
1,567 |
78,544 |
83,860 |
| Pauwels Eric | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
50.10 |
1,378 |
69,032 |
85,427 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Feb 20 '25 |
Sale |
50.12 |
3,895 |
195,233 |
276,038 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
50.10 |
3,897 |
195,224 |
279,933 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Feb 20 '25 |
Sale |
50.12 |
962 |
48,219 |
76,894 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Feb 19 '25 |
Sale |
50.10 |
795 |
39,826 |
77,856 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Feb 20 '25 |
Sale |
50.12 |
1,614 |
80,900 |
103,901 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):